Clinical Trials
39 trialsNCT04975958 2025-06-22
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
Adlai Nortye Biopharma Co., Ltd.
Phase 1 Completed
NCT02113878 2024-11-05
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01971489 2023-04-27
Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT01570296 2023-03-29
BKM120
National Cancer Centre, Singapore
Phase 1 Completed
NCT02756247 2022-10-10
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02117817 2022-07-28
Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
Rutgers, The State University of New Jersey
Phase 1 Withdrawn
NCT01540253 2022-07-22
PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic
Roswell Park Cancer Institute
Phase 1 Completed
NCT02049541 2022-06-30
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01623349 2021-02-10
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01468688 2020-12-21
A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients
Novartis
Phase 1 Completed
NCT01576666 2020-12-19
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02154776 2020-12-19
LeeBLet
Novartis
Phase 1 Completed
NCT02088684 2020-12-17
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
Novartis
Phase 1 Completed
NCT01155453 2020-12-09
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients
Novartis
Phase 1 Completed
NCT01285466 2020-12-09
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
Novartis
Phase 1 Completed
NCT01473901 2020-12-09
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Novartis
Phase 1 Completed
NCT01626209 2020-12-09
A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01634061 2020-12-09
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
Novartis
Phase 1 Completed
NCT01934361 2020-12-09
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Novartis
Phase 1 Completed
NCT01068483 2020-12-08
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
Novartis
Phase 1 Completed
NCT01283503 2020-12-08
A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01363232 2020-10-05
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
Array BioPharma
Phase 1 Completed
NCT02058381 2020-03-09
B-YOND
Novartis
Phase 1 Completed
NCT02614508 2019-09-03
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Emory University
Phase 1 Terminated
NCT02128724 2019-08-01
BKM120
University of Oxford
Phase 1 Completed
NCT01741753 2019-02-05
BKM120+Abiraterone Acetate for Metastatic CRPC
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT01820325 2018-10-11
BASALT-2
Novartis
Phase 1 Terminated
NCT01911325 2018-08-14
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients
Novartis
Phase 1 Terminated
NCT02439489 2018-06-20
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors
Fondazione Michelangelo
Phase 1 Completed
NCT01470209 2018-03-19
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Emory University
Phase 1 Completed
NCT02194049 2018-01-09
Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer
University of California, Davis
Phase 1 Completed
NCT02487823 2017-11-17
NCMPC-BKM
Institut Paoli-Calmettes
Phase 1 Terminated
NCT01571024 2017-04-26
BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT01297452 2017-03-31
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01339442 2017-01-25
BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer
Washington University School of Medicine
Phase 1 Completed
NCT01304602 2017-01-06
A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer
University of Kansas Medical Center
Phase 1 Completed
NCT01396499 2016-11-01
Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01723800 2016-09-20
PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer
City of Hope Medical Center
Phase 1 Completed
NCT01248494 2016-07-25
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Completed